Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 13-14/2021

29.04.2021 | original article

The role of quantitative HBsAg in patients with HBV DNA between 2000–20,000 IU/ml

verfasst von: MD Sibel Yıldız Kaya, MD Assoc Prof. Bilgül Mete, MD Abdurrahman Kaya, MD Assoc Prof. Ilker Inanç Balkan, MD Prof. Neşe Saltoglu, MD Prof. Ömer Fehmi Tabak

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 13-14/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Aims

We aimed to determine the contribution of quantitative HBsAg in differentiating chronic infections from chronic hepatitis in HBeAg negative patients with HBV DNA 2000–20,000 IU/ml.

Material and methods

A total of 79 untreated HBeAg negative patients were included. Patients were divided into 3 groups based on HBV DNA levels: group 1 (HBV DNA ≤ 2000 IU/ml), group 2 (HBV DNA: 2000–20,000 IU/ml) and group 3 (HBV DNA > 20,000 IU/ml). We collected serum from all patients for quantitative HBsAg analysis. We compared serum quantitative HBsAg levels with biochemical parameters, HBV DNA and liver biopsy results.

Results

In this study 46 patients were female and the mean age was 42 years. Serum quantitative HBsAg levels were found to be significantly lower in chronic infections compared with chronic hepatitis. There was a positive correlation between quantitative HBsAg and HBV DNA, ALT (alanine aminotransferase), HAI score (histological activity index), fibrosis score and disease stage. The cut-off level of quantitative HBsAg was determined as 4425 IU/ml to differentiate chronic infection from chronic hepatitis. With the test specificity of 95%, we found quantitative HBsAg cut-off values 1026 IU/ml and 20,346 IU/ml for the diagnosis of chronic infection and chronic hepatitis, respectively.

Conclusion

Our study suggests that the quantitative HBsAg ≤ 1000 IU/ml limit value might be used for the diagnosis of chronic infection not only in HBV DNA ≤ 2000 IU/ml but also in patients with HBV DNA between 2000–20,000 IU/ml. In addition, antiviral treatment could be considered in patients with quantitative HBsAg > 20,000 IU/ml and HBV DNA > 2000 IU/ml without further examinations such as liver biopsy.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
2.
Zurück zum Zitat Liang TJ. Hepatitis B : the virus and disease. 2009. pp. 13–21. Liang TJ. Hepatitis B : the virus and disease. 2009. pp. 13–21.
4.
Zurück zum Zitat Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog. J Gastroenterol. 2013;48:13–21. PubMedCrossRef Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog. J Gastroenterol. 2013;48:13–21. PubMedCrossRef
5.
Zurück zum Zitat Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res. 1994;23:251–7. PubMedCrossRef Janssen HL, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on alpha-interferon therapy. Antiviral Res. 1994;23:251–7. PubMedCrossRef
6.
Zurück zum Zitat Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–90. PubMedCrossRef Brunetto MR, Oliveri F, Colombatto P, Moriconi F, Ciccorossi P, Coco B, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483–90. PubMedCrossRef
7.
Zurück zum Zitat Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. CrossRef Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. CrossRef
8.
Zurück zum Zitat Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, et al. Quantification of HBsAg in nucleos ( t ) ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015;62:56–63. PubMedCrossRef Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, et al. Quantification of HBsAg in nucleos ( t ) ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015;62:56–63. PubMedCrossRef
9.
Zurück zum Zitat Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol. 2012;56:1254–8. PubMedCrossRef Fasano M, Lampertico P, Marzano A, Di Marco V, Niro GA, Brancaccio G, et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol. 2012;56:1254–8. PubMedCrossRef
10.
Zurück zum Zitat Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, et al. Response to peginterferon alfa-2a ( 40KD ) in HBeAg-negative CHB : On-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013;59:1153–9. PubMedCrossRef Brunetto MR, Marcellin P, Cherubini B, Yurdaydin C, Farci P, Hadziyannis SJ, et al. Response to peginterferon alfa-2a ( 40KD ) in HBeAg-negative CHB : On-treatment kinetics of HBsAg serum levels vary by HBV genotype. J Hepatol. 2013;59:1153–9. PubMedCrossRef
11.
Zurück zum Zitat Seto W, Wong DK, Fung J, Huang F, Liu KS, Lai C, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Eur Soc Clin Infect Dis. 2014;20:1173–80. Seto W, Wong DK, Fung J, Huang F, Liu KS, Lai C, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Eur Soc Clin Infect Dis. 2014;20:1173–80.
12.
Zurück zum Zitat Brunetto MR, Moriconi F, Bonino F. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141–50. PubMedCrossRef Brunetto MR, Moriconi F, Bonino F. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141–50. PubMedCrossRef
14.
Zurück zum Zitat Wisedopas N, Poovorawan Y, Tangkijvanich P. Kinetics of serum HBsAg and Intrahepatic cccDNA during Pegylated interferon terapy in patients with HbeAg-positive and HbeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130–8. PubMedCrossRef Wisedopas N, Poovorawan Y, Tangkijvanich P. Kinetics of serum HBsAg and Intrahepatic cccDNA during Pegylated interferon terapy in patients with HbeAg-positive and HbeAg-negative chronic hepatitis B. J Med Virol. 2017;89:130–8. PubMedCrossRef
15.
Zurück zum Zitat Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56–S61. PubMedCrossRef Bréchot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56–S61. PubMedCrossRef
16.
Zurück zum Zitat Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Pract Res Clin Gastroenterol. 2014;31:281–9. CrossRef Höner zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Pract Res Clin Gastroenterol. 2014;31:281–9. CrossRef
17.
Zurück zum Zitat Association E. EASL Clinical Practice Guidelines : management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85. CrossRef Association E. EASL Clinical Practice Guidelines : management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85. CrossRef
18.
Zurück zum Zitat Terrault NA, Bzowej NH, Chang K‑M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83. PubMedCrossRef Terrault NA, Bzowej NH, Chang K‑M, Hwang JP, Jonas MM, Murad MH. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–83. PubMedCrossRef
19.
Zurück zum Zitat Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. PubMedCrossRef Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98. PubMedCrossRef
20.
Zurück zum Zitat Iloeje U, Yang H, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86. PubMedCrossRef Iloeje U, Yang H, Su J, Jen C, You S, Chen C. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86. PubMedCrossRef
21.
Zurück zum Zitat Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9. PubMedPubMedCentralCrossRef Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9. PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Larsson SB, Hannoun C, Lindh M, Malmstro S. Hepatitis B viral DNA decline at loss of HbeAg is mainly explained by reduced cccDNA load—down-regulated transcription of PgRNA has limited impact. Plos One. 2012;7:e36349. PubMedPubMedCentralCrossRef Larsson SB, Hannoun C, Lindh M, Malmstro S. Hepatitis B viral DNA decline at loss of HbeAg is mainly explained by reduced cccDNA load—down-regulated transcription of PgRNA has limited impact. Plos One. 2012;7:e36349. PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Weng M, Zeng W, Wu X, Zhang Y, Jiang M, Wang Z, et al. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure. Virol J. 2013;10:1. CrossRef Weng M, Zeng W, Wu X, Zhang Y, Jiang M, Wang Z, et al. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure. Virol J. 2013;10:1. CrossRef
24.
Zurück zum Zitat Janssen HLA, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen : is it useful for the management of chronic hepatitis B ? Gut. 2012;61:641–5. PubMedCrossRef Janssen HLA, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen : is it useful for the management of chronic hepatitis B ? Gut. 2012;61:641–5. PubMedCrossRef
25.
Zurück zum Zitat Chan HL, Thompson A, Martinot-peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Review hepatitis B surface antigen quantification : why and how to use it in 2011—A core group report. J Hepatol. 2011;55:1121–31. PubMedCrossRef Chan HL, Thompson A, Martinot-peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Review hepatitis B surface antigen quantification : why and how to use it in 2011—A core group report. J Hepatol. 2011;55:1121–31. PubMedCrossRef
26.
Zurück zum Zitat Alghamdi A, Aref N, El-Hazmi M, Al-Hamoudi W, Alswat K, Helmy A, et al. Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol. 2013;19:252–7. PubMedPubMedCentralCrossRef Alghamdi A, Aref N, El-Hazmi M, Al-Hamoudi W, Alswat K, Helmy A, et al. Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol. 2013;19:252–7. PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Sali S, Sharafi H, Hoda S, Moayed S, Etesam F. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state ? Diagn Microbiol Infect Dis. 2015;82:114–9. PubMedCrossRef Sali S, Sharafi H, Hoda S, Moayed S, Etesam F. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state ? Diagn Microbiol Infect Dis. 2015;82:114–9. PubMedCrossRef
28.
Zurück zum Zitat Balkan A, Namıduru M, Balkan Y, Mete AÖ, Karaoğlan İ. Are serum quantitative hepatitis B surface antigen levels , liver histopathology and viral loads related in chronic hepatitis B—infected patients ? Saudi J Gastroenterol. 2016;22:208–14. PubMedPubMedCentralCrossRef Balkan A, Namıduru M, Balkan Y, Mete AÖ, Karaoğlan İ. Are serum quantitative hepatitis B surface antigen levels , liver histopathology and viral loads related in chronic hepatitis B—infected patients ? Saudi J Gastroenterol. 2016;22:208–14. PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Nguyen T, Thompson AJV, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B : a perspective on Asia. J Hepatol. 2010;52:508–13. PubMedCrossRef Nguyen T, Thompson AJV, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B : a perspective on Asia. J Hepatol. 2010;52:508–13. PubMedCrossRef
31.
Zurück zum Zitat Michelle M‑P, Lapalus M, Laouénan C, Boyer N, -Pierre Ripault M, Asselah T, et al. How to distinguish HBeAg negative chronic hepatitis B, with high risk of reactivation, from inactive carriers: Is there a place for HBsAg quantification? Hepatology. 2012;56:434A–5A. Michelle M‑P, Lapalus M, Laouénan C, Boyer N, -Pierre Ripault M, Asselah T, et al. How to distinguish HBeAg negative chronic hepatitis B, with high risk of reactivation, from inactive carriers: Is there a place for HBsAg quantification? Hepatology. 2012;56:434A–5A.
32.
Zurück zum Zitat Tseng T, Liu C, Yang H, Su T, Wang C, Chen C, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–9. PubMedCrossRef Tseng T, Liu C, Yang H, Su T, Wang C, Chen C, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–9. PubMedCrossRef
Metadaten
Titel
The role of quantitative HBsAg in patients with HBV DNA between 2000–20,000 IU/ml
verfasst von
MD Sibel Yıldız Kaya
MD Assoc Prof. Bilgül Mete
MD Abdurrahman Kaya
MD Assoc Prof. Ilker Inanç Balkan
MD Prof. Neşe Saltoglu
MD Prof. Ömer Fehmi Tabak
Publikationsdatum
29.04.2021
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 13-14/2021
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-021-01854-7